Fagoterapia frente a bacterias multirresistentes
DOI:
https://doi.org/10.35381/s.v.v8i1.3919Palabras clave:
Antibacterianos, antifúngicos, uso terapéutico, (Fuente: DeCS)Resumen
Objetivo: Analizar la fago terapia frente a bacterias multirresistentes. Método: Descriptivo documental. Conclusión: La fagoterapia ofrece una esperanza real para el tratamiento de infecciones bacterianas, especialmente aquellas causadas por microorganismos multirresistentes a los antibióticos. Sin embargo, se necesitan más investigaciones, ensayos clínicos y regulaciones adecuadas para su desarrollo y adopción más amplia en la práctica clínica.
Descargas
Citas
Hatfull GF, Dedrick RM, Schooley RT. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med. 2022;73:197-211. https://doi.org/10.1146/annurev-med-080219-122208
Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17-31. https://doi.org/10.1016/j.cell.2022.11.017
Suh GA, Lodise TP, Tamma PD, et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022;66(3):e0207121. https://doi.org/10.1128/AAC.02071-21
Xu HM, Xu WM, Zhang L. Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases. Int J Clin Pract. 2022;2022:4913146. https://doi.org/10.1155/2022/4913146
Luong T, Salabarria AC, Roach DR. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?. Clin Ther. 2020;42(9):1659-1680. https://doi.org/10.1016/j.clinthera.2020.07.014
Tagliaferri TL, Jansen M, Horz HP. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy. Front Cell Infect Microbiol. 2019;9:22. https://doi.org/10.3389/fcimb.2019.00022
Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. Viruses. 2018;11(1):18. https://doi.org/10.3390/v11010018
Onallah H, Hazan R, Nir-Paz R, et al. Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series. Med. 2023;4(9):600-611.e4. https://doi.org/10.1016/j.medj.2023.07.002
Torres-Barceló C, Hochberg ME. Evolutionary Rationale for Phages as Complements of Antibiotics. Trends Microbiol. 2016;24(4):249-256. https://doi.org/10.1016/j.tim.2015.12.011
Royer S, Morais AP, da Fonseca Batistão DW. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Arch Microbiol. 2021;203(4):1271-1279. https://doi.org/10.1007/s00203-020-02167-5
Ferry T, Kolenda C, Briot T, et al. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection. Viruses. 2021;13(12):2414. https://doi.org/10.3390/v13122414
Patil A, Banerji R, Kanojiya P, Koratkar S, Saroj S. Bacteriophages for ESKAPE: role in pathogenicity and measures of control. Expert Rev Anti Infect Ther. 2021;19(7):845-865. https://doi.org/10.1080/14787210.2021.1858800
Mohan Raj JR, Karunasagar I. Phages amid antimicrobial resistance. Crit Rev Microbiol. 2019;45(5-6):701-711. https://doi.org/10.1080/1040841X.2019.1691973
Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021;68:151-159. https://doi.org/10.1016/j.copbio.2020.11.003
Valério N, Oliveira C, Jesus V, et al. Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Res. 2017;240:8-17. https://doi.org/10.1016/j.virusres.2017.07.015
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Mario David Pinta-Riofrio, Paola Monserrath Jiménez-Espinosa, Melany Alexandra Suárez-Jurado, Washington Paúl Culqui-Molina
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
